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HIV latency is a major barrier to viral eradication from infected individuals. Lusic et al. (2013) show that HIV
latency is established by spatially positioning the proviral chromatin in close proximity to promyelocytic
leukemia (PML) nuclear bodies, a reversible process that recruits the methyltransferase enzyme G9a to
the latent viral promoter.The nucleus of eukaryotic cells is highly
organized. Emerging evidence indicates
that the location of distinct genes within
the nucleus is tightly regulated, can
change during different transcriptional
states, and affects their transcriptional
activity (Bridger, 2011). When viruses
such as HIV integrate into the host
chromatin, their transcription is strongly
influenced by the local chromatin environ-
ment at the site of integration (Jordan
et al., 2001). HIV preferentially infects
activated CD4+ T cells, where it generally
establishes a highly productive life cycle
that ultimately leads to the destruction of
the infected host cell within days after
infection. In a small subset of infected
cells, mainly central memory T cells, the
viral life cycle is silenced at the transcrip-
tional level, and the virus establishes a
stable latent reservoir that remains unaf-
fected by current antiretroviral regimens
(Han et al., 2007). This latent reservoir
represents one of the major barriers to
HIV eradication in infected patients on
antiretroviral therapy, but the molecular
mechanisms responsible for proviral la-
tency are only incompletely understood.
In this issue of Cell Host & Microbe,
Marina Lusic, Mauro Giacca, and col-
leagues present evidence that proximity
of the integrated HIV genome to the
nuclear body defined by the PML protein
plays an important role in latency (Lusic
et al., 2013). Using 3D-fluorescent in situ
hybridization combined with immuno-
staining, they examined the location of
the integrated HIV genome in latently
infected cells with respect to the PML
body. Using three different J-Lat clonal
cells lines, a model for HIV latency
obtained after infection of the Jurkat
lymphoid cell line (Jordan et al., 2003),they observed colocalization of latent
HIV with the PML nuclear body (Figure 1).
This colocalization was lost after reactiva-
tion of latent HIV with either the phorbol
ester tetradecanoyl phorbol acetate
(TPA) or the histone deacetylase inhibitor
SAHA. Similar results were obtained using
a model for HIV latency in human primary
CD4+ T cells developed by Alberto Bos-
que and Vicente Planelles (Bosque and
Planelles, 2009). As further support for a
role of the PML nuclear bodies in latency,
they observed that PML removal by
shRNA-mediated knockdown of PML or
by treatment of latent cells with arsenic
trioxide (which induces PML degradation)
is associated with transcriptional activa-
tion of latent HIV. This was also observed
in J-Lat cell lines and in the primary CD4+
T cell latency model.
PML nuclear bodies are highly dynamic
nuclear structures with extensive contact
to chromatin and direct links to transcrip-
tional activation and repression of unique
genes. Besides the PML protein, its main
structural component, they contain tran-
scriptional corepressors, such as Daxx,
that PML helps to recruit to nuclear
bodies and gene promoters. Importantly,
the authors show that transcriptional
repression of latent HIV does not depend
on Daxx but on the PML-dependent
recruitment of the methyltransferase G9a
(Figure 1). G9a mediates dimethylation
of histone H3K9 (H3K9me2), a known
mark of facultative heterochromatin
within euchromatic regions. Using chro-
matin immunoprecipitation, the authors
foundG9a and theH3K9me2modification
at the latent, but not the reactivated, HIV
provirus, underscoring the link between
PML nuclear bodies, epigenetic chro-
matin modifications, and HIV latency.Cell Host & MicrobeAn interesting aspect of the paper is the
connection to actin-mediated chromatin
movement. The rapid and potentially
nonrandom relocation of genes within
the nucleus implies the presence of
molecular motors, similar to those found
in the cytoplasm. Actin, long regarded
as a cytoplasmic contaminant of nuclear
preparations, is now an established
nuclear regulator of gene expression and
is found in many nuclear complexes,
including those associating with the RNA
polymerase II C-terminal domain and
in chromatin-remodeling complexes. In a
number of reported cases, repositioning
of specific genes to different regions of
the genome is dependent on active
nuclear actin polymerization (Vartiainen
et al., 2012). Importantly, Lusic and col-
leagues show that treatment of latently
infected cells with cytochalasin D, an in-
hibitor of actin polymerization, prevented
the relocalization of the HIV genome
away from PML nuclear bodies and
suppressed reactivation of latent HIV in
response to phorbol esters. In addition,
they report that actin itself binds to the
transcriptionally activated, and not to the
latent, HIV promoter, opposite to what
is observed for PML (Figure 1). This obser-
vation indicates a direct function for actin
in the transcriptional activation of the HIV
provirus. Thus, the HIV provirus joins a
growing group of genes that are regulated
at the transcriptional level by nuclear
topology. Despite a significant number
of examples connecting gene movement
with changes in transcriptional activity, it
is still unclear whether intranuclear move-
ment of chromatin is the cause or result of
changes in transcriptional activity.
Interestingly, nuclear bodies defined
by the PML protein are also implicated in13, June 12, 2013 ª2013 Elsevier Inc. 625
Figure 1. Regulation of HIV Latency by Proximity to the PML Nuclear Body
Under latency conditions, the HIV provirus is positioned in close proximity to PML nuclear bodies. PML
recruits the methyltransferase G9a to the HIV promoter, leading to dimethylation of lysine 9 in histone
H3 and transcriptional silencing. Upon treatment with the phorbol ester TPA, the deacetylase inhibitor
SAHA, or arsenic trioxide, a compound inducing PML degradation, the HIV provirus is relocated away
from PML nuclear bodies, and HIV transcription is activated.
Cell Host & Microbe
Previewsthe life cycle of other nuclear-replicating
DNA viruses and some retroviruses. The
genomes of herpes simplex virus 1 and
cytomegalovirus, two human herpesvi-
ruses, also associate with the PML nu-
clear bodies under restrictive conditions
such as latency (Everett, 2001). The fact
that two of the nuclear body proteins,
PML and Sp100, are induced by inter-
feron has raised the possibility that the
PML nuclear body might represent part
of the innate immune response to DNA
viruses.
How might this insight benefit HIV-
infected individuals? One strategy to
eradicate HIV from infected individuals
is to reverse latency under the cover
of intense antiretroviral therapy and to
induce the ‘‘flushing’’ of long-lived latently626 Cell Host & Microbe 13, June 12, 2013 ªinfected T cells. This ‘‘shock and kill’’
approach to purging the latent HIV reser-
voir is being directly tested in patients
with HDAC inhibitors, such as SAHA
(vorinostat), that induce reactivation of
latent HIV in cell culture and in infected
individuals (Archin et al., 2012; Van Lint
et al., 1996). Interestingly, this paper
shows that SAHA treatment is associated
with the repositioning of the HIV genome
away from the closest PML nuclear
body, suggesting that PML and histone
deacetylases could act in concert to
repress HIV transcription under latency
conditions. In addition, the authors
identify an agent, arsenic trioxide, as a
potent reactivator of latent HIV. Arsenic
trioxide, a poison used therapeutically
in ancient Chinese medicine and today2013 Elsevier Inc.as an anticancer treatment, induces
PML degradation. In addition, it induces
degradation of the oncogenic PML fusion
proteins, such as PML-RARa, and is an
approved drug (Trisenox) for refractory
promyelocytic leukemia (Zhang et al.,
2010). The finding that it potently acti-
vates HIV from latency in cell lines and
primary T cells adds an approved drug
to the list of latency-reversing compounds
with clinical potential.REFERENCES
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